100+ Free ABTS Thoracic Surgery Practice Questions

Pass your ABTS Thoracic and Cardiac Surgery Certifying Examination exam on the first try — instant access, no signup required.

✓ No registration✓ No credit card✓ No hidden fees✓ Start practicing immediately

~80-90% first-time pass rate on the Written Qualifying Examination (ABTS annual statistics) Pass Rate

100+ Questions

100% Free

1 / 100

Question 1

Score: 0/0

In the PARTNER 3 trial 5-year follow-up, how did TAVR with the balloon-expandable Sapien 3 compare with surgical AVR in low-risk patients with severe aortic stenosis?

TAVR was markedly superior in all-cause mortality at 5 years

Surgical AVR had significantly lower stroke and death at 5 years

The primary composite of death, stroke, or rehospitalization was similar between arms, with no significant difference at 5 years

TAVR was associated with significantly less paravalvular leak than SAVR

to track

2026 Statistics

Key Facts: ABTS Thoracic Surgery Exam

~275

Total MCQ Items

ABTS Written Qualifying Examination (~250-300 range)

~8 hr

Total Exam Time

1-day computer-based test including breaks

~37%

General Thoracic Weight

Largest single domain on 2026 ABTS content outline

~$2,500

2026 Written Qualifying Fee

ABTS (verify current schedule)

6 yr

Integrated I-6 Pathway

ACGME-accredited integrated cardiothoracic surgery residency

~80-90%

First-Time Pass Rate

ABTS annual statistics (Written Qualifying)

The ABTS Written Qualifying Examination is a 1-day computer-based test from the American Board of Thoracic Surgery comprising ~250-300 single-best-answer MCQs over ~8 hours at Pearson VUE. Content blueprint: Adult Cardiac ~31%, General Thoracic ~37%, Aorta ~9%, Congenital ~9%, Critical Care & Perioperative ~7%, Thoracic Trauma ~4%, Ethics/Statistics ~3%. Written Qualifying fee is ~$2,500; requires completion of an ACGME-accredited thoracic surgery residency (traditional or integrated I-6 pathway).

Sample ABTS Thoracic Surgery Practice Questions

Try these sample questions to test your ABTS Thoracic Surgery exam readiness. Each question includes a detailed explanation. Start the interactive quiz above for the full 100+ question experience with AI tutoring.

1In the PARTNER 3 trial 5-year follow-up, how did TAVR with the balloon-expandable Sapien 3 compare with surgical AVR in low-risk patients with severe aortic stenosis?

A.TAVR was markedly superior in all-cause mortality at 5 years

B.Surgical AVR had significantly lower stroke and death at 5 years

C.The primary composite of death, stroke, or rehospitalization was similar between arms, with no significant difference at 5 years

D.TAVR was associated with significantly less paravalvular leak than SAVR

Explanation: PARTNER 3 5-year data (Mack NEJM 2023) showed no statistically significant difference between TAVR and SAVR for the primary composite (death/stroke/rehospitalization) in low-risk patients, with early TAVR advantage attenuating over time. Paravalvular leak and pacemaker rates remained higher with TAVR. Long-term durability remains under evaluation.

2Per the ACC/AHA 2020 Valvular Heart Disease Guideline (2023 focused update), which is a Class I indication for intervention in asymptomatic severe aortic stenosis?

A.Peak aortic jet velocity 3.5 m/s with normal LV function

B.LVEF <50% attributable to aortic stenosis

C.Aortic valve area 1.2 cm² with preserved function

D.Mild symptoms only with exertion

Explanation: Class I indications for AVR in severe AS include: symptomatic severe AS (stage D1), asymptomatic severe AS with LVEF <50% (stage C2), and severe AS undergoing other cardiac surgery. LVEF <50% attributable to AS defines stage C2 and is a Class I trigger for intervention regardless of symptoms.

3A 58-year-old diabetic with three-vessel CAD and SYNTAX score of 32 is referred. Based on FREEDOM and SYNTAX data, which strategy is preferred?

A.PCI with drug-eluting stents

B.Medical therapy alone

C.CABG with arterial grafting

D.Hybrid coronary revascularization

Explanation: FREEDOM (NEJM 2012) demonstrated CABG superiority over PCI in diabetics with multivessel disease for MACCE at 5 years. SYNTAX showed CABG favored for intermediate (23-32) and high (>32) SYNTAX scores. Current ACC/AHA 2021 coronary revascularization guidelines give CABG a Class I recommendation over PCI in diabetics with multivessel disease.

4The EXCEL and NOBLE trials evaluated PCI vs CABG in unprotected left main disease. What is the most accurate synthesis of their long-term results?

A.Both trials clearly favored PCI at 5 years

B.Both trials clearly favored CABG for all-cause mortality

C.EXCEL showed similar composite outcomes but higher all-cause mortality with PCI at 5 years; NOBLE favored CABG for MACCE

D.Both trials showed no difference in stroke or MI

Explanation: EXCEL 5-year data showed similar composite primary outcome but higher all-cause mortality with PCI (13.0% vs 9.9%). NOBLE 5-year data showed CABG superiority for MACCE driven by lower non-procedural MI and repeat revascularization. Current guidelines give CABG Class I for left main; PCI IIa for low-complexity LM (SYNTAX ≤22).

5The ISCHEMIA trial (NEJM 2020) included patients with moderate-to-severe ischemia. What was the key finding at median 3.2-year follow-up?

A.Invasive strategy reduced cardiovascular death or MI

B.Initial invasive strategy did not reduce the primary composite of cardiovascular events compared with optimal medical therapy

C.CABG was inferior to medical therapy

D.Mortality was significantly lower with invasive strategy

Explanation: ISCHEMIA demonstrated no significant reduction in cardiovascular events with an initial invasive strategy versus optimal medical therapy in stable CAD with moderate-to-severe ischemia. Invasive strategy improved angina-related quality of life. Left main disease was excluded. This has shaped 2021 ACC/AHA guidelines emphasizing OMT as foundation.

6The Arterial Revascularization Trial (ART) 10-year results examined single vs bilateral internal thoracic artery grafting. What did they show?

A.BITA significantly reduced all-cause mortality at 10 years

B.The intention-to-treat analysis showed no significant difference in mortality, but as-treated and per-protocol analyses suggested BITA benefit

C.BITA doubled the rate of death

D.SITA was inferior for graft patency

Explanation: ART 10-year ITT analysis (Taggart NEJM 2019) showed no significant mortality difference between SITA and BITA, though crossover (~14%) complicated interpretation. As-treated analyses favored multiple arterial grafting. RADIAL meta-analysis supports radial artery over SVG as second conduit. LITA-LAD remains Class I.

7In the RADIAL investigators pooled analysis, the radial artery vs saphenous vein as a second conduit was associated with:

A.Higher occlusion and increased mortality with radial

B.Improved clinical outcomes (composite MACE) and lower occlusion with radial artery

C.No difference in graft patency

D.Higher sternal wound infection with radial

Explanation: Gaudino et al. (NEJM 2018, JAMA 2020) pooled individual patient data from 6 RCTs showing radial artery grafts had significantly lower occlusion, lower repeat revascularization, and lower composite MACE versus saphenous vein. This supports preferential use of radial as second conduit in suitable targets.

8A 72-year-old with primary severe degenerative MR from posterior leaflet prolapse, EF 62%, LVESD 42 mm, NYHA II, is referred. Which is the best recommendation?

A.Continue medical therapy and follow in 1 year

B.MitraClip (TEER) given age

C.Mitral valve repair at an experienced mitral center (Class I)

D.Mitral valve replacement with bioprosthesis

Explanation: ACC/AHA 2020 guidelines: symptomatic severe primary MR is Class I for intervention. With posterior leaflet prolapse at an experienced center (>95% repair rate, <1% mortality), durable repair is strongly preferred and is Class I. MitraClip (TEER) is reserved for prohibitive/high-risk surgical candidates in primary MR.

9The COAPT trial established a role for transcatheter edge-to-edge repair (TEER) with MitraClip in which population?

A.Primary degenerative MR with preserved EF

B.Secondary (functional) MR in symptomatic heart failure with GDMT, EF 20-50%, moderate-to-severe MR

C.Mitral stenosis with rheumatic disease

D.Ischemic MR after acute MI

Explanation: COAPT (Stone NEJM 2018) randomized symptomatic HF patients with moderate-to-severe secondary MR despite maximal GDMT to TEER + GDMT vs GDMT alone, showing reduced heart failure hospitalization and all-cause mortality at 24 months. MITRA-FR was negative, likely due to smaller MR with larger LV (disproportionate MR hypothesis).

10Which is the most common cause of failed mitral valve repair in the first year?

A.Annular ring dehiscence

B.Endocarditis

C.Systolic anterior motion (SAM)

D.Residual or recurrent regurgitation from incomplete repair

Explanation: The leading cause of early repair failure is residual/recurrent MR from incomplete leaflet or chordal repair — missed clefts, inadequate resection, failure to address anterior leaflet pathology, or undersized annuloplasty allowing residual prolapse. Late failure includes leaflet remodeling and new chordal rupture. SAM is a recognized but less common post-repair complication.

About the ABTS Thoracic Surgery Exam

The ABTS Thoracic and Cardiac Surgery Certifying Examination is a two-part sequence — a Written Qualifying Examination followed by an Oral Certifying Examination. This listing covers the Written Qualifying portion, which validates core knowledge across adult cardiac surgery (ischemic, valvular, heart failure and transplant, MCS), general thoracic surgery (lung cancer, esophageal, mediastinal, benign esophagus, pleura and chest wall), aorta and great vessels, congenital cardiac surgery, critical care and perioperative management, thoracic trauma, and ethics/statistics. Content integrates the ACC/AHA 2020 Valve Guideline (2023 update), 2022 Aortic Disease Guideline, AJCC 8 staging, NCCN 2026, and landmark trials (PARTNER 2/3, Evolut Low Risk, EXCEL/NOBLE, COAPT, TRILUMINATE, PINNACLE FLX, LAAOS III, FREEDOM, ISCHEMIA, MOMENTUM 3 HeartMate 3, ADAURA, IMpower010, CheckMate 816/577/743, CROSS, FLOT4, CALGB 140503/JCOG 0802, INSTEAD-XL, EOLIA). Requires completion of an ACGME-accredited thoracic surgery residency (traditional 2-3 years post general surgery or integrated I-6 6 years).

Questions

275 scored questions

Time Limit

1-day CBT (~8 hours including breaks)

Passing Score

Criterion-referenced scaled score set by ABTS (modified Angoff standard)

Exam Fee

~$2,500 Written Qualifying Examination fee (ABTS 2026 — verify current schedule) (American Board of Thoracic Surgery (ABTS) / Pearson VUE)

ABTS Thoracic Surgery Exam Content Outline

~37%

General Thoracic Surgery

Lung cancer (AJCC 8 NSCLC staging; CALGB 140503/JCOG 0802 — sublobar noninferior to lobectomy for ≤2 cm peripheral with clear margins; ADAURA — adjuvant osimertinib for resected EGFR+ stage IB-IIIA; IMpower010 — adjuvant atezolizumab for PD-L1+ stage II-IIIA; CheckMate 816 — neoadjuvant nivolumab + chemotherapy for resectable stage IB-IIIA; NCCN 2026), SBRT alternative in medically inoperable stage I, preoperative pulmonary assessment (ppoFEV1 >40%, ppoDLCO >40%, VO2 max >15 mL/kg/min for lobectomy), mediastinum (thymoma Masaoka-Koga staging, thymectomy for myasthenia gravis — MGTX RCT), esophageal cancer (AJCC 8; CROSS — neoadjuvant CRT carboplatin/paclitaxel for esophageal SCC/adeno; FLOT4 — perioperative docetaxel/oxaliplatin/5-FU for gastric/GEJ; CheckMate 577 — adjuvant nivolumab after neoadjuvant CRT and R0 resection; Ivor Lewis vs McKeown vs transhiatal; minimally invasive esophagectomy), achalasia (Heller myotomy + partial fundoplication, POEM), GERD and paraesophageal hernia (Nissen/Toupet), tracheal resection, pleural disease (MPE, PleurX, pleurodesis, VATS decortication), chest wall.

~31%

Adult Cardiac Surgery

Ischemic heart disease (FREEDOM — CABG superior to PCI in diabetics with multivessel CAD; ISCHEMIA — initial invasive vs OMT in stable CAD; arterial revascularization — LIMA-LAD standard, bilateral IMA/radial for younger patients; off-pump vs on-pump CABG), valvular heart disease (ACC/AHA 2020 Valve Guideline + 2023 focused update; PARTNER 2 intermediate, PARTNER 3 5-year low-risk; Evolut Low Risk 4-year — TAVR vs SAVR; EXCEL/NOBLE — left main PCI vs CABG; COAPT — MitraClip for secondary MR with HF; TRILUMINATE — tricuspid TEER; PINNACLE FLX — Watchman FLX in AF; LAAOS III — concomitant LAA occlusion at cardiac surgery reduces stroke), atrial fibrillation surgery (Cox maze IV, cryomaze), heart failure and transplantation (UNOS 6-tier allocation 2018; donor matching; MOMENTUM 3 5-year HeartMate 3 — fully magnetically levitated centrifugal; BiVAD/TAH), pericardial disease, cardiac tumors (myxoma).

~9%

Aorta & Great Vessels

2022 ACC/AHA Aortic Disease Guideline, thoracic aortic aneurysm thresholds (ascending ≥5.5 cm general, ≥5.0 cm Marfan/Loeys-Dietz/vEDS, ≥5.5 cm bicuspid aortic valve, or rapid growth), valve-sparing aortic root replacement (David V reimplantation, Yacoub remodeling), acute aortic syndromes (Stanford A — emergent open repair; Stanford B — TEVAR for complicated, endovascular-first; INSTEAD-XL — TEVAR + OMT reduces 5-year aortic-related mortality in uncomplicated B; IRAD registry data), arch surgery (total arch, frozen elephant trunk, antegrade cerebral perfusion, DHCA), connective tissue disease (Marfan FBN1 — fibrillin-1; Loeys-Dietz TGFBR1/2 — more aggressive; vascular Ehlers-Danlos COL3A1), blunt aortic injury at isthmus — TEVAR first-line.

~9%

Congenital Cardiac Surgery

Shunt physiology (Qp:Qs; left-to-right — VSD, ASD secundum/primum, AVSD, PDA; right-to-left cyanotic — TOF, TGA, tricuspid atresia, obstructed TAPVR, truncus arteriosus), single ventricle palliation (Norwood stage 1 — Sano RV-PA vs modified BT shunt; bidirectional Glenn stage 2 at 4-6 months; Fontan completion stage 3 at 2-4 years), HLHS, tetralogy of Fallot (transannular patch, pulmonary valve-sparing, late pulmonary valve replacement), TGA (arterial switch operation — Jatene, Lecompte maneuver; atrial switch — Mustard/Senning historical), Ebstein anomaly (Cone reconstruction), coarctation (end-to-end vs subclavian flap vs extended end-to-end), interrupted aortic arch (DiGeorge 22q11.2), Rastelli for DORV/TGA/VSD/PS, Ross procedure (pulmonary autograft).

~7%

Critical Care & Perioperative

Cardiopulmonary bypass (heparin dosing with ACT >480; protamine reversal; HIT and bivalirudin/argatroban alternatives; hemodilution and blood conservation; DHCA with antegrade or retrograde cerebral perfusion; cerebral NIRS monitoring), myocardial protection (antegrade/retrograde cardioplegia, del Nido single-dose, cold blood, topical hypothermia), mechanical circulatory support (IABP — augments diastolic/reduces afterload; Impella 2.5/CP/5.5; VA-ECMO for cardiogenic shock; VV-ECMO for severe ARDS — EOLIA trial), low cardiac output syndrome and post-cardiotomy shock, vasoplegia after CPB (methylene blue, hydroxocobalamin), perioperative AF prophylaxis (beta-blocker, amiodarone), ARDS (lung-protective 6 mL/kg, prone positioning, ECMO — EOLIA).

~4%

Thoracic Trauma

Blunt and penetrating cardiac injury (Beck's triad — hypotension, muffled heart sounds, JVD; FAST; pericardial window or subxiphoid; ED thoracotomy for penetrating chest with signs of life lost en route — survival best for isolated penetrating cardiac), blunt aortic injury at ligamentum arteriosum isthmus (TEVAR first-line per SVS/ATLS), tracheobronchial injury, pulmonary contusion and flail chest, diaphragmatic rupture (left more common), massive hemothorax (operative threshold ≥1500 mL initial or ≥200 mL/hr for 2-4 hours), esophageal perforation (Boerhaave — spontaneous distal left; iatrogenic — most common; contained vs free, surgery vs endoscopic stent).

~3%

Ethics, Statistics & Professionalism

Informed consent for high-risk cardiothoracic procedures with mortality and major-morbidity disclosure, STS National Database quality metrics and risk-adjusted outcomes (STS risk score), shared decision-making for TAVR vs SAVR across risk strata and MitraClip vs surgical MR repair, professionalism and disclosure of conflicts, end-of-life and futility discussions in LVAD/MCS (destination therapy vs bridge), biostatistics (sensitivity/specificity, PPV/NPV, Kaplan-Meier survival, Cox proportional hazards, NNT, propensity matching), research design (RCT, registry, propensity-matched cohort), levels of evidence.

How to Pass the ABTS Thoracic Surgery Exam

What You Need to Know

Passing score: Criterion-referenced scaled score set by ABTS (modified Angoff standard)
Exam length: 275 questions
Time limit: 1-day CBT (~8 hours including breaks)
Exam fee: ~$2,500 Written Qualifying Examination fee (ABTS 2026 — verify current schedule)

Keys to Passing

Complete 500+ practice questions
Score 80%+ consistently before scheduling
Focus on highest-weighted sections
Use our AI tutor for tough concepts

ABTS Thoracic Surgery Study Tips from Top Performers

1TAVR vs SAVR across risk strata (2026 high-yield): PARTNER 2 intermediate-risk and PARTNER 3 low-risk (5-year follow-up showed no difference in death/stroke vs SAVR); Evolut Low Risk 4-year similarly noninferior. Heart team decision incorporates age (younger favor SAVR for durability data), anatomy (bicuspid, LVOT calcium, annulus size, vascular access), lifecycle management, and concomitant disease (CABG, MV disease, ascending aneurysm). ACC/AHA 2020 Valve Guideline (2023 focused update) codifies these pathways.

2Lung cancer 2026 perioperative therapy: CheckMate 816 — neoadjuvant nivolumab + platinum-doublet chemotherapy for resectable stage IB-IIIA NSCLC improves EFS and pCR. ADAURA — adjuvant osimertinib for resected EGFR-mutant stage IB-IIIA NSCLC improves DFS and OS. IMpower010 — adjuvant atezolizumab for PD-L1+ resected stage II-IIIA NSCLC. CALGB 140503 / JCOG 0802 — sublobar resection (segmentectomy preferred) noninferior to lobectomy for peripheral ≤2 cm clinical stage IA with adequate margins and nodal staging.

3Single ventricle palliation staged pathway (Norwood → Glenn → Fontan): Stage 1 Norwood in first week of life — Damus-Kaye-Stansel + aortic arch reconstruction + either modified BT shunt or Sano RV-PA conduit (SVR trial — Sano early survival better, BT better late). Stage 2 bidirectional Glenn at 4-6 months — SVC to PA, removes ventricular volume load. Stage 3 Fontan at 2-4 years — IVC to PA (extracardiac or lateral tunnel), achieving total cavopulmonary connection. Know Fontan-associated liver disease and protein-losing enteropathy long-term.

42022 ACC/AHA Aortic Disease Guideline thresholds: Ascending aortic aneurysm repair ≥5.5 cm general; ≥5.0 cm Marfan/Loeys-Dietz/vEDS; ≥5.5 cm bicuspid aortic valve (or ≥5.0 cm with risk factors); rapid growth ≥0.5 cm/year; concomitant with other cardiac surgery at ≥4.5 cm. Valve-sparing root (David V reimplantation) preferred in young patients with competent tricuspid aortic valve. Acute Stanford A — emergent open repair. Stanford B — TEVAR for complicated (malperfusion, rupture, refractory pain/hypertension); INSTEAD-XL — TEVAR + OMT reduces aortic-related mortality in uncomplicated B.

5LAAOS III (concomitant LAA occlusion at cardiac surgery in AF patients) reduced ischemic stroke/systemic embolism ~33% at 3.8 years with no increase in bleeding. COAPT — MitraClip (TEER) for secondary MR in HF with GDMT reduced HF hospitalization and all-cause mortality at 24 months (vs MITRA-FR negative result — key difference: COAPT had larger ERO/smaller LV, i.e., disproportionate MR). TRILUMINATE — tricuspid TEER reduced MR grade and improved quality of life vs medical therapy (no mortality benefit). MOMENTUM 3 5-year — HeartMate 3 fully magnetically levitated centrifugal LVAD superior to axial HeartMate II (fewer pump thromboses, strokes, reoperations).

Frequently Asked Questions

What is the ABTS Thoracic and Cardiac Surgery Certifying Examination?

The ABTS Thoracic and Cardiac Surgery Certifying Examination is a two-part sequence administered by the American Board of Thoracic Surgery: a Written Qualifying Examination followed by an Oral Certifying Examination. This listing covers the Written Qualifying portion. Together the two parts lead to initial board certification in thoracic surgery, covering adult cardiac, general thoracic, aorta, congenital cardiac, critical care, trauma, and ethics/statistics. Candidates must pass the Written Qualifying before becoming eligible for the Oral.

Who is eligible to take the ABTS Written Qualifying Examination?

Candidates must complete an ACGME-accredited thoracic surgery residency — either the traditional pathway (ACGME-accredited general surgery residency plus 2-3 years of thoracic surgery residency) or the integrated I-6 pathway (6 years of integrated cardiothoracic surgery residency). A valid unrestricted medical license is required, the program director must attest to satisfactory performance and ethics, and candidates must submit a qualifying case list per ABTS requirements.

What is the format of the ABTS Written Qualifying Exam?

The ABTS Written Qualifying Examination is a 1-day computer-based test administered at Pearson VUE test centers, comprising approximately 250-300 single-best-answer multiple-choice questions over roughly 8 hours including breaks. Items routinely include echocardiograms, CT images, angiograms, CXR, pathology, and intraoperative photos. The exam is blueprinted to the ABTS content outline — Adult Cardiac ~31%, General Thoracic ~37%, Aorta ~9%, Congenital ~9%, Critical Care ~7%, Trauma ~4%, Ethics/Statistics ~3%.

How much does the 2026 ABTS Written Qualifying Exam cost?

The 2026 ABTS Written Qualifying Examination fee is approximately $2,500 — always verify the current schedule on the ABTS website. Candidates also pay a separate Oral Certifying Examination fee (~$2,600) after passing Written. Cancellation and refund policies follow the ABTS schedule with decreasing refunds as the exam date approaches. Retakes require re-registration and full fee payment within the allowed qualification window.

When is the 2026 exam administered?

The ABTS Written Qualifying Examination is typically offered once annually. Applications generally open several months before the test with a submission deadline per ABTS schedule. Candidates schedule specific appointments with Pearson VUE after application approval. The Oral Certifying Examination follows separately after Written is passed. Exact 2026 dates should be confirmed on the ABTS certification page.

How is the exam scored?

ABTS uses criterion-referenced scaled scoring with a passing standard set by subject-matter experts using the modified Angoff method. A candidate's pass/fail result depends on performance relative to the fixed cut-score, not on other candidates. Score reports include domain-level feedback. Candidates must pass the Written Qualifying before becoming eligible for the Oral Certifying Examination, which is an in-person case-based oral assessment.

What are the highest-yield topics?

Highest-yield topics include valve surgery decision-making (PARTNER 3 5-year low-risk, Evolut LR 4-year, EXCEL/NOBLE LM, COAPT MitraClip, LAAOS III concomitant LAA occlusion), ACC/AHA 2020 Valve + 2023 update thresholds, 2022 Aortic Disease Guideline (aneurysm thresholds, INSTEAD-XL TEVAR, valve-sparing root, frozen elephant trunk), FREEDOM CABG vs PCI in diabetics, lung cancer neoadjuvant/adjuvant (CheckMate 816, ADAURA, IMpower010; CALGB 140503/JCOG 0802 sublobar), esophageal neoadjuvant (CROSS, FLOT4, CheckMate 577), MOMENTUM 3 HeartMate 3, single ventricle palliation (Norwood/Glenn/Fontan), TGA Jatene, connective tissue disease genes (FBN1, TGFBR1/2, COL3A1), and blunt aortic injury TEVAR.

How should I study for this exam?

Use a structured 12-18 month plan layered on residency. Map to the ABTS content outline: begin with adult cardiac (ischemic, valve, MCS, transplant), then general thoracic (lung, esophagus, mediastinum, pleura), aorta, congenital, critical care and CPB, trauma, and ethics/statistics. Integrate textbooks (Cohn/Adams Cardiac Surgery in the Adult, Shields' General Thoracic Surgery, Kouchoukos Kirklin/Barratt-Boyes, Jonas Comprehensive Surgical Management of Congenital Heart Disease), SESATS review, STS annual meeting updates, landmark trials (PARTNER, Evolut, COAPT, EXCEL, ADAURA, CheckMate 816, CROSS, FREEDOM, ISCHEMIA, MOMENTUM 3, INSTEAD-XL, LAAOS III), and high-volume MCQ practice. Complete 2-3 full-length timed mock exams.